These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21671851)

  • 1. The changing face of multiple sclerosis clinical trial populations.
    Uitdehaag BM; Barkhof F; Coyle PK; Gardner JD; Jeffery DR; Mikol DD
    Curr Med Res Opin; 2011 Aug; 27(8):1529-37. PubMed ID: 21671851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using routine data to complement and enhance the results of randomised controlled trials.
    Lewsey JD; Leyland AH; Murray GD; Boddy FA
    Health Technol Assess; 2000; 4(22):1-55. PubMed ID: 11074392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What can be learned from open direct comparative trials in multiple sclerosis?
    Khan O
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Actual status of multiple sclerosis in Cuba. National cooperative group for the clinical trial "Recombinant interferon alpha-2b in multiple sclerosis"].
    Cabrera-Gómez JA; Santana-Capote E; Echazábal-Santana N; Díaz de la Fe A; Casanova M; Gómez L; Báez-Martín MM; González-Quevedo A; Fernández R; Vals O; Peña A; Rodríguez A; Cabrera-Núñez JA; Moscoso ME; Ruiz M
    Rev Neurol; 2000 Sep 1-15; 31(5):482-93. PubMed ID: 11027103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity.
    Goodkin DE; Rudick RA; VanderBrug Medendorp S; Greene T; Schwetz KM; Fischer J; Daughtry MM; Ross J; Van Dyke C
    Online J Curr Clin Trials; 1992 Sep; Doc No 19():[7723 words; 89 paragraphs]. PubMed ID: 1343611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D
    Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
    Zhao Y; Traboulsee A; Petkau AJ; Li D
    Neurology; 2008 Mar; 70(13 Pt 2):1092-7. PubMed ID: 18003938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nocebo effects in multiple sclerosis trials: a meta-analysis.
    Papadopoulos D; Mitsikostas DD
    Mult Scler; 2010 Jul; 16(7):816-28. PubMed ID: 20538704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of methodological issues of clinical trials in multiple sclerosis.
    Montalban X
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S35-42. PubMed ID: 22206765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatoid arthritis: disease-modifying antirheumatic drugs.
    Kirwan JR; Currey HL
    Clin Rheum Dis; 1983 Dec; 9(3):581-99. PubMed ID: 6360514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.